Drug Safety Meta-Analysis: Promises and Pitfalls

被引:0
|
作者
Michael A. Stoto
机构
[1] School of Nursing and Health Studies,Department of Health Systems Administration
[2] Georgetown University,undefined
来源
Drug Safety | 2015年 / 38卷
关键词
Major Depressive Disorder; Naproxen; Rosiglitazone; Rofecoxib; Risk Difference;
D O I
暂无
中图分类号
学科分类号
摘要
Meta-analysis has increasingly been used to identify adverse effects of drugs and vaccines, but the results have often been controversial. In one respect, meta-analysis is an especially appropriate tool in these settings. Efficacy studies are often too small to reliably assess risks that become important when a medication is in widespread use, so meta-analysis, which is a statistically efficient way to pool evidence from similar studies, seems like a natural approach. But, as the examples in this paper illustrate, different syntheses can come to qualitatively different conclusions, and the results of any one analysis are usually not as precise as they seem to be. There are three reasons for this: the adverse events of interest are rare, standard meta-analysis methods may not be appropriate for the clinical and methodological heterogeneity that is common in these studies, and adverse effects are not always completely or consistently reported. To address these problems, analysts should explore heterogeneity and use random-effects or more complex statistical methods, and use multiple statistical models to see how dependent the results are to the choice of models.
引用
收藏
页码:233 / 243
页数:10
相关论文
共 50 条
  • [1] Drug Safety Meta-Analysis: Promises and Pitfalls
    Stoto, Michael A.
    [J]. DRUG SAFETY, 2015, 38 (03) : 233 - 243
  • [2] Promises and pitfalls of meta-analysis in vaccine research
    Jacobson, RM
    [J]. VACCINE, 1999, 17 (13-14) : 1628 - 1634
  • [3] Pitfalls in meta-analysis
    Palmowski, Andriko
    Nielsen, Sabrina M.
    [J]. INFLAMMOPHARMACOLOGY, 2020, 28 (02) : 617 - 618
  • [4] Pitfalls in meta-analysis
    Andriko Palmowski
    Sabrina M. Nielsen
    [J]. Inflammopharmacology, 2020, 28 : 617 - 618
  • [5] Pooling, meta-analysis, and the evaluation of drug safety
    Michel Lièvre
    Michel Cucherat
    Alain Leizorovicz
    [J]. Current Controlled Trials in Cardiovascular Medicine, 2002, 3
  • [6] Meta-analysis: pitfalls and hints
    Greco, T.
    Zangrillo, A.
    Biondi-Zoccai, G.
    Landoni, G.
    [J]. HEART LUNG AND VESSELS, 2013, 5 (04) : 219 - 225
  • [7] Meta-analysis - Its role in assessing drug safety
    Henry, D
    Hill, S
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 1999, 8 (03) : 167 - 168
  • [8] Limitations of meta-analysis, drug safety remain uncertain
    Gabb, G. M.
    Ronson, S.
    [J]. INTERNAL MEDICINE JOURNAL, 2016, 46 (05) : 640 - 641
  • [9] Meta-analysis of drug safety data with logistic regression
    Lee M.-L.T.
    Lazarus R.
    [J]. Drug information journal : DIJ / Drug Information Association, 1997, 31 (4): : 1189 - 1193
  • [10] Promises and Pitfalls of Calcineurin Inhibitors in COVID-19: A Systematic Review and Meta-analysis of Controlled Trials
    Heydari, Behrooz
    Sahebnasagh, Adeleh
    Omrani, Mohammad Ali
    Azimi, Saeed
    Dehghani, Mohammad Hossein
    Salehi-Abargouei, Amin
    Farman, Farnoosh
    Saghafi, Fatemeh
    [J]. CURRENT MEDICINAL CHEMISTRY, 2024, 31 (29) : 4745 - 4755